利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.025 秒)

    Prostate-specific membrane antigen antibody drug conjugates
    1.
    发明授权
    Prostate-specific membrane antigen antibody drug conjugates 有权

    公开(公告)号：US10800856B2

    公开(公告)日：2020-10-13

    申请号：US14406190

    申请日：2013-06-07

    申请人： Ambrx, Inc.

    发明人： Richard S. Barnett ,  Feng Tian ,  Anna-Maria A. Hays Putnam ,  Marco Gymnopoulos ,  Nick Knudsen ,  Andrew Beck ,  Ying Sun

    IPC分类号： A61K47/68 ,  A61K49/00 ,  C07K16/40 ,  C07K16/30 ,  C07K5/02

    摘要： This invention relates to prostate-specific membrane antigen (PSMA) antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are αPSMA antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the αPSMA antibodies of the invention are conjugated to one or more toxins. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, dolastatin analogs, and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology uses.

    PROSTATE-SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATES
    5.
    发明申请
    PROSTATE-SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATES 有权

    公开(公告)号：US20220033518A1

    公开(公告)日：2022-02-03

    申请号：US17003952

    申请日：2020-08-26

    申请人： Ambrx,Inc.

    发明人： Richard Barnett ,  Feng Tian ,  Anna-Maria A. Hays Putnam ,  Marco Gymnopoulos ,  Nickolas Knudsen ,  Andrew Beck ,  Ying Sun

    IPC分类号： C07K16/40 ,  C07K16/30 ,  C07K5/02 ,  A61K47/68

    摘要： This invention relates to prostate-specific membrane antigen (PSMA) antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are αPSMA antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the αPSMA antibodies of the invention are conjugated to one or more toxins. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, dolastatin analogs, and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology uses.

    Prostate-Specific Membrane Antigen Antibody Drug Conjugates
    6.
    发明申请
    Prostate-Specific Membrane Antigen Antibody Drug Conjugates 审中-公开
    前列腺特异性膜抗原抗体药物缀合物

    公开(公告)号：US20150152190A1

    公开(公告)日：2015-06-04

    申请号：US14406190

    申请日：2013-06-07

    申请人： Ambrx, Inc.

    发明人： Richard S. Barnett ,  Feng Tian ,  Anna-Maria A. Hays Putnam ,  Marco Gymnopoulos ,  Nick Knudsen ,  Andrew Beck ,  Ying Sun

    IPC分类号： C07K16/40 ,  C07K7/06

    摘要： This invention relates to prostate-specific membrane antigen (PSMA) antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are αPSMA antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the αPSMA antibodies of the invention are conjugated to one or more toxins. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, dolastatin analogs, and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology uses.

    摘要翻译： 本发明涉及包含至少一种非天然编码氨基酸的前列腺特异性膜抗原（PSMA）抗体和抗体药物偶联物。 本文公开了具有一种或多种非天然编码氨基酸的αPSMA抗体，并且还公开了抗体药物偶联物，其中本发明的αPSMA抗体与一种或多种毒素缀合。 本文还公开了在翻译后进一步修饰的非天然氨基酸多拉司他汀类似物，用于实现这种修饰的方法，以及纯化这种多拉司他汀类似物的方法。 通常，修饰的多拉司他汀类似物包括至少一个肟，羰基，二羰基和/或羟胺基团。 进一步披露的是使用这种非天然氨基酸抗体药物偶联物，多拉司他汀类似物和经修饰的非天然氨基酸多拉司他汀类似物的方法，包括治疗，诊断和其他生物技术用途。